You are here
New drugs and the economic dilemma facing them.
Professor Jean Bousquet discusses the importance of drug and treatment cost effectiveness.
Prof Bousquet states that dozens of biologics are appearing every year for many diseases, and it can be argued that paying a high cost for treatment of a rare disease is acceptable. However, in Europe, the number of people with rare diseases is 30 million. Thus, paying €20-30,000/patient/year is not affordable for governments, so they must choose; rare diseases are at the top of the list, followed by cancers, and asthma falls somewhere in the middle. The biggest dilemma facing the biologics in asthma treatment is the cost. Hence to justify using them, we must effectively stratify patients to ensure that the best treatment is being given to an individual patient, particularly when using very costly drugs.